Pimecrolimus: Skin disposition after topical administration in minipigs in vivo and in human skin in vitro

European Journal of Pharmaceutical Sciences

Volumn 33, Issue 1, 2008, Pages 9-19

  Gschwind, Hans Peter ^a   Waldmeier, Felix ^a   Zollinger, Markus ^a   Schweitzer, Alain ^a   Grassberger, Maximilian ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Institutes for BioMedical Research Vienna   (Austria)

Author keywords

Human skin; Metabolism; Minipig; Pimecrolimus; Radiolabel; Skin penetration

Indexed keywords

PIMECROLIMUS; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG METABOLISM; EPIDERMIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MINIPIG; NONHUMAN; PRIORITY JOURNAL; SKIN; SKIN SURFACE; STRATUM CORNEUM; TOXICOKINETICS;

ADMINISTRATION, CUTANEOUS; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CALCINEURIN; CHROMATOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; SKIN; SKIN ABSORPTION; SWINE; SWINE, MINIATURE; TACROLIMUS; TRITIUM;

EID: 36849068918     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.09.004     Document Type: Article

References (24)

1. Allen B.R., Lakhanpaul M., Morris A., Lateo S., Davies T., Scott G., Cardno M., Ebelin M.E., Burtin P., and Stephenson T.J. Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch. Dis. Child. 88 (2003) 969-973
2. Barry B.W. Structure, function, disease, and topical treatment of human skin. Dermatological Formulations. Percutaneous Absorption. Drugs and the Pharmaceutical Sciences vol. 18 (1983), Marcel Decker Inc., New York 1-48
3. Billich A., Aschauer H., Aszody A., and Stuetz A. Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharm. 269 (2004) 29-35
4. Eichenfield L.F., and Beck L. Elidel (pimecrolimus) cream 1%: a non-steroidal topical agent for the treatment of atopic dermatitis. J. Allergy Clin. Immunol. 111 (2003) 1154-1168
5. Epstein W.L., and Maibach H.I. Cell renewal in human epidermis. Arch. Dermatol. 92 (1965) 462-468
6. Franz, T.J., Lehman, P.A., McGuire, E.L., 1992. In vivo methods for the assessment of percutaneous absorption in man. In: Zatz, J. (Ed.), Percutaneous Absorption: Allured Wheaton, IL, pp. 72-89.
7. Graham-Brown R.A., and Grassberger M. Pimecrolimus: a review of preclinical and clinical data. Int. J. Clin. Pract. 57 (2003) 319-327
8. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., Schuler W., Schulz M., Werner F.J., Winiski A., Wolff B., and Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br. J. Dermatol. 141 (1999) 264-273
9. Lakhanpaul M., Davies T., Allen B.R., and Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp. Dermatol. 15 (2006) 138-141
10. Lakhanpaul, M., Davies, T., Allen, B., Stephenson, T., Scott, G., Ebelin, M.E., 2002. Pimecrolimus (SDZ ASM 981) cream 1%: minimal systemic absorption in infants with atopic dermatitis during long-term treatment (Conference abstract). 20th World Congress of Dermatology, Paris, July 1-5, 2002. Ann. Dermatol. Venereol. 129, 1S415.
11. Meingassner J.G., Aschauer H., Stuetz A., and Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed or corticosteroid pre-treated skin. Exp. Dermatol. 14 (2005) 752-757
12. Moenius, T., Baumann, K., Bulusu, M., Schweitzer, A., Voges, R., 2001. Labeling of pharmacologically active macrocycles. In: Proceedings of the Seventh International Symposium, Dresden, Germany, June 18-22, 2000. Pleiss, U. (Ed.), Synthesis and Applications of Isotopically Labeled Compounds, vol. 7. John Wiley & Sons, Chichester, pp. 424-429.
13. Mortensen J.T., Brinck P., and Lichtenberg J. The minipig in dermal toxicology: a literature review. Scand. J. Lab. Anim. Sci. 25 Suppl. 1 (1998) 77-83
14. Namiki Y., Kihara N., Koda S., Hane K., and Yasuda T. Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution. I. Isolation and structure determination of tautomeric compounds. J. Antibiot. (Tokyo) 46 (1993) 1149-1155
15. Rothberg S., Crounse R.G., and Lee J.L. Glycine-C-14-incorporation into the proteins of normal stratum corneum and the abnormal stratum corneum of psoriasis. J. Invest. Dermatol. 37 (1961) 497-505
16. Schmook F.P., Meingassner J.G., and Billich A. Comparison of human skin or epidermis models with human and animal skin in in vitro percutaneous absorption. Int. J. Pharm. 215 (2001) 51-56
17. Simon G.A., and Maibach H.I. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations-an overview. Skin Pharmacol. Appl. Skin Physiol. 13 (2000) 229-234
18. ®) in infants with atopic dermatitis-a multicenter, 3-week, open-label study. Pediatr. Dermatol. 22 (2005) 465-471
19. ®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 204 (2002) 63-68
20. Van Leent, E.J.M., De Vries, H.J.C., Ebelin, M.E., Bos, J.D., 2002. Low blood concentrations of pimecrolimus (SDZ ASM 981) in adult atopic dermatitis patients treated topically for up to 1 year (conference abstract). In: 60th Annual Meeting of the American Academy of Dermatology, New Orleans.
21. Weinstein G.D., and Van Scott E.J. Autoradiographic studies of turnover time and protein synthesis in pig epidermis. J. Invest. Dermatol. 45 (1965) 257-262
22. Wellington K., and Noble N. Pimecrolimus: a review of its use in atopic dermatitis. Am. J. Clin. Dermatol. 5 (2004) 479-495
23. Wolff K., and Stuetz A. Pimecrolimus for the treatment of inflammatory skin diseases. Review. Expert Opin. Pharmacother. 5 (2004) 643-655
24. Zollinger M., Waldmeier F., Hartmann S., Zenke G., Zimmerlin A.G., Glaenzel U., Baldeck J.-P., Schweitzer A., Berthier S., Moenius T., and Grassberger M.A. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers following a single oral dose and supplementary investigations in vitro. Drug Metab. Dispos. 34 (2006) 765-774